Laddar...

Development of a drug–disease simulation model for rituximab in follicular non-Hodgkin's lymphoma

AIM: Rituximab has dramatically improved the survival of patients with non-Hodgkin's lymphomas (NHL), but the dosing regimen currently used should be optimized. However, the concentration–effect relationship of rituximab has never been described by pharmacokinetic–pharmacodynamic (PK–PD) modell...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Ternant, David, Hénin, Emilie, Cartron, Guillaume, Tod, Michel, Paintaud, Gilles, Girard, Pascal
Materialtyp: Artigo
Språk:Inglês
Publicerad: Blackwell Science Inc 2009
Ämnen:
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2780281/
https://ncbi.nlm.nih.gov/pubmed/19843059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2009.03494.x
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!